- Si****ucel-T, sold
under the
brand name
Provenge,
developed by
Dendreon Pharmaceuticals, LLC, is a cell-based
cancer immunotherapy for
prostate cancer...
-
Dendreon is a
biotechnology company. Its lead product,
Provenge (known
generically as si****ucel-T), is an
immunotherapy for
prostate cancer. It consists...
- US
Corporation Dendreon which is in
trials with a
cancer vaccine called Provenge. [citation needed] List of
South Korean companies "Cj제일제당 : 네이버 금융". Archived...
-
Dendreon Corporation announced that
their Phase III
clinical trial of
Provenge, a
cancer vaccine designed to
treat prostate cancer, had
demonstrated an...
-
vaccine is delivered. The best
known dendritic cell
vaccine is Si****ucel-T (
Provenge),
which only
improved survival by four months. The
efficacy of dendritic...
-
their immune system is not able to
produce enough efficient antibodies.
Provenge,
developed by Dendreon, was the
first therapeutic vaccine approved by the...
- 8950. PMID 19471115. S2CID 23222462.
Cheever MA,
Higano CS (June 2011). "
PROVENGE (Si****ucel-T) in
prostate cancer: the
first FDA-approved
therapeutic cancer...
- in
antitumor DC-based
clinical trials.[citation needed] Si****ucel-T (
Provenge) was
approved for
treatment of
asymptomatic or
minimally symptomatic metastatic...
-
demonstrated on the U.S. Food and Drug
Administration (FDA)-approved TCV
Provenge. It was
first tested on
breast cancer patients with
tumors expressing HER2/neu...
-
Mahmoud Goodarzi 2010 – The
first autologous cell-based
cancer vaccine,
Provenge, is
approved by the FDA for the
treatment of metastatic,
asymptomatic stage...
